Shionogi Company Limited

Hokkaido University

Junji Onoda

Tatsuya Takahashi

Yoshito Numata

Shoichi Naito

Shoji Yamane

Katsutoshi Yamada

Kazuhiko Maekawa

Tasuku Tsukamoto

Akira Yamauchi

Shin-Ichiro Nishimura

Naoki Ohyabu

Etsuo Nakamura

Erika Kasai

Sosuke Yoneda

Tsuguo Miyauchi

Toshiyuki Asaki

Mai Yoshikawa

Atsushi Morita

Junji Kishono

Hiroshi Hinou

Isao Fukuda

Hidekuni Yamakawa

Kouhei Nishitomi

Yasunobu Yoshida

Yasuhiko Sato

Objective of the present invention is to provide a novel monoclonal antibody against Nav1.7. The present invention discloses a monoclonal antibody against Nav1.7 or its antibody fragment, having specific six CDRs (CDR1 to CDR3 of a heavy chain and CDR1 to CDR3 of a light chain) or specific heavy/light chain variable regions. The monoclonal antibody and the like can be used for treating or preventing pain, pruritus and so on.

Monoclonal antibody against Nav1.7

Provided is a monoclonal antibody or a fragment thereof that selectively inhibits the enzymatic activity of vascular endothelial lipase and pharmaceutical compositions containing the same as an active ingredient useful for the treatment of arteriosclerosis or metabolic syndrome.

Method of inhibiting the enzymatic activity of vascular endothelial lipase with a monoclonal antibody

Monoclonal antibody, inhibiting the enzymatic activity of vascular endothelial lipase

Provided is a monoclonal antibody or a fragment thereof that selectively inhibits enzyme activity of EL and pharmaceutical compositions containing the same as an active ingredient useful for the treatment of arteriosclerosis or metabolic syndrome.

Monoclonal antibody against EL which inhibits enzyme activity of EL

Provided are a monoclonal antibody capable of specifically recognizing a specific region of sAPP &#x3b2; or a fragment of said antibody and an assay method and an assay kit using the same, in order to accurately assay sAPP&#x3b2; contained in a biological sample.

Anti-sAPP&#x3b2; antibody

An object of the present invention is to provide an antibody which does not bind to a normal cell, and is specific for a cancer cell. The object was solved by the finding by the present inventors that an antibody obtained by immunizing an animal using a 2,3ST glycopeptide as an antigen unexpectedly recognizes a sugar chain specific for a cancer specifically and remarkably, and consequently, can recognize and kill a cancer cell expressing MUC1 having such a cancer cell-specific sugar chain. The present invention provides, for example, an antibody, an antigen-binding fragment thereof or a MUC1-binding molecule, in which specificity for a cancer-associated structure of MUC1 is 100-fold or more as compared with that for a normal tissue-associated structure of MUC1.

Anti-MUC1 antibody

A neutralizing monoclonal antibody specifically reacting with MMP13, a method of neutralizing enzyme activity of MMP13 and an immunological measuring method each using the antibody, as well as a diagnostic agent and a pharmaceutical composition containing the antibody, are provided. Various antibodies to MMP13 have been hitherto obtained, but an antibody having neutralizing activity against MMP13 has not been obtained. The present inventors intensively studied, as a result, found out a neutralizing antibody having specificity for MMP13, resulting in completion of the present invention.

Monoclonal antibody having neutralizing activity against MMP13

Growing community of inventors

Toyonaka, Japan

Junji Onoda